Related Experiment Video
Updated: Jan 1, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Targeting iNOS As a Valuable Strategy for the Therapy of Glioma
Cristina Maccallini1, Marialucia Gallorini1, Amelia Cataldi1
1Department of Pharmacy, University G. d'Annunzio, Via dei Vestini 31, 66100, Chieti, Italy.
Abstract:
Gliomas are the most prevalent primary tumors of the brain and spinal cord. Histologically, they share features of normal glial cells, but whether gliomas originate from normal glial cells, glial or neural precursors, stem cells, or other cell types remains a topic of investigation. The enhanced expression of inducible nitric oxide synthase (iNOS) has been reported as a hallmark of chemoresistance in gliomas, and several lines of evidence have reported that a decreased proliferation of glioma cells could be related to the selective inhibition of iNOS. This review aims to summarize the current understanding of iNOS expression and activity modulation in the regulation of glioma pathogenesis, along with compounds that could act as therapeutic agents against glioma.
Insights
This review explores inducible nitric oxide synthase (iNOS) in glioma, a common brain tumor. Inhibiting iNOS may reduce glioma cell proliferation and enhance chemoresistance, offering potential therapeutic strategies.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Biochemistry
Background:
- Gliomas are primary brain and spinal cord tumors with glial cell features.
- The origin of gliomas from various cell types is under investigation.
- Enhanced inducible nitric oxide synthase (iNOS) expression is linked to chemoresistance in gliomas.
Purpose of the Study:
- To review the role of iNOS expression and activity in glioma pathogenesis.
- To summarize compounds that may act as therapeutic agents against gliomas.
Main Methods:
- Literature review of iNOS in glioma.
- Analysis of iNOS expression and activity modulation.
- Identification of potential therapeutic compounds targeting iNOS.
Main Results:
- iNOS expression is a hallmark of chemoresistance in gliomas.
- Selective inhibition of iNOS is associated with decreased glioma cell proliferation.
Conclusions:
- Modulation of iNOS offers a potential therapeutic strategy for glioma treatment.
- Targeting iNOS may overcome chemoresistance and inhibit tumor growth.
